Evidence map›Paper›PMID 40781261›Full record

ArticleScientific reports2025

Clinical and pathological features of lymphomas in the breast: a comprehensive multicentric study.

Umberto Maccio, Anton Rets, Claudia Grosse, Nicholas Andrew Ferguson, Rupert Langer, Marco Matteo Bühler, Alessandra Gallo, Isabel Witzel, Christine Beham-Schmid, Jann Wieler and 2 more

Abstract readMulticenter Study
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Umberto MaccioDepartment of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland. umberto.maccio@usz.ch.
Anton RetsDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA.
Claudia GrosseDepartment of Pathology and Molecular Pathology, Johannes Kepler University Linz, Kepler University Hospital GmbH, Linz, Austria.
Nicholas Andrew FergusonDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA.
Rupert LangerDepartment of Pathology and Molecular Pathology, Johannes Kepler University Linz, Kepler University Hospital GmbH, Linz, Austria.
Marco Matteo BühlerDepartment of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland.
Alessandra GalloDepartment of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland.
Isabel WitzelDepartment of Gynecology, University Hospital of Zurich, Zurich, Switzerland.
Christine Beham-SchmidDepartment of Pathology and Molecular Pathology, Ordensklinikum Linz, Linz, Austria.
Jann WielerDepartment of Radiology, Triemli Hospital Zurich, Zurich, Switzerland.
Maria OrsariaInstitute of Pathological Anatomy, "Santa Maria della Misericordia" University Hospital, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.
Zsuzsanna VargaDepartment of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast lymphomas, though rare, present a unique spectrum of clinical and pathological characteristics. This multicenter retrospective study evaluates 92 cases from four international institutions over a ten-year period to provide a comprehensive analysis of primary breast lymphomas (PBLs), secondary breast lymphomas (SBLs), and related subtypes, including breast implant-associated lymphomas (BIA-ALCL) and intra-mammary lymph node lymphomas. Primary breast lymphomas accounted for 46.7% of cases, with a predominance of diffuse large B-cell lymphoma (DLBCL). Secondary breast involvement, observed in 43.5% of cases, displayed a more diverse histological distribution, with follicular lymphoma being the most common subtype. Breast implant-associated lymphomas (BIA-ALCL) constituted 6.5% of cases, exclusively involving anaplastic large cell T-cell lymphoma, ALK-negative. The study highlights significant differences in patient demographics, clinical presentation, and survival outcomes. PBLs primarily affected older patients (mean age: 68.4 years) and were associated with longer lymphoma-specific survival compared to SBLs (76.12 vs. 59.45 months; p = 0.001). Notably, survival differences were evident within histological subtypes, emphasizing the impact of disease origin on prognosis. BIA-ALCL cases were distinct in clinical features and histology, with a younger mean age (47.5 years) and frequent association with unilateral effusion. This analysis underscores the necessity for precise diagnostic and therapeutic strategies tailored to the unique biology of breast lymphomas. Future research should aim to elucidate molecular mechanisms and optimize management protocols to improve patient outcomes.

Indexed as

Breast NeoplasmsLymphomaAdultAgedAged, 80 and overBreast ImplantsFemaleHumansLymphoma, Large-Cell, AnaplasticMiddle AgedPrognosisRetrospective StudiesBIA-ALCLBreast lymphomaBreast pathologyIntramammary lymph nodes

Identifiers

PMID40781261
PMCPMC12334564

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.